Risk factors for mortality in users of ibopamine

British Journal of Clinical Pharmacology

Volumn 46, Issue 1, 1998, Pages 71-77

  Feenstra, J ^a,b   In't Veld, B A ^a,b   Van Der Linden, P D ^b   Grobbee, D E ^c   Stricker, B H Ch ^a,b  

^a Drug Safety Unit   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Ibopamine; Mortality; Risk factors

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COUMARIN DERIVATIVE; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBOPAMINE; LOOP DIURETIC AGENT; NITRATE; OPIATE AGONIST; SALICYLIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CREATININE BLOOD LEVEL; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE;

AGED; COHORT STUDIES; DEOXYEPINEPHRINE; DOPAMINE AGONISTS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; RISK FACTORS;

EID: 0031831658     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00046.x     Document Type: Article

References (19)

1. Henwood JM, Todd PA. Ibopamine. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1988; 36: 11-31.
2. Spencer C, Faulds D, Fitton A. Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure. Drugs Aging 1993; 3: 556-584.
3. Lopez-Sendon J. Ibopamine in chronic congestive heart failure: hemodynamic and neurohumoral effects. Am J Med 1991; 90 (5B): 43S-49S.
4. Lieverse AG, van Veldhuisen DJ, Smit AJ, et al. Renal and systemic hemodynamic effects of ibopamine in patients with mild to moderate congestive heart failure. J Cardiovasc Pharmacol 1995; 25: 361-367.
5. Cowie MR, Mosterd A, Wood DA, et al. Epidemiology of heart failure. Eur Heart J 1997; 18 (2): 208-225.
6. Man in't Veld AJ. Ibopamine in the treatment of heart failure. Am J Med 1991; 90 (5B): 50S-54S.
7. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Res Group N Engl J Med 1991; 325 (21): 1468-1475.
8. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group N Engl J Med 1993; 329 (3): 149-155.
9. Condorelli M, Bonaduce A, Montemurro A, et al. The long-term efficacy of ibopamine in treating patients with severe heart failure: a multicenter investigation. J Cardiovasc Pharmacol 1989; 14(Suppl 8): S83-S92.
10. Caponnetto S, Terrachini V, Canale C, Bruzzone F, Licciardello L, Marchetti GV. Absence of proarrhythmic effects of ibopamine in patients with congestive heart failure. J Cardiovasc Pharmacol 1989; 14(Suppl 8): S104-S110.
11. Rolandi E, Sabino F, Cantoni V, Ghirardi P, Marchetti GV, Cicchetti V. Long-term therapy of chronic congestive heart failure with ibopamine: a multicenter trial. J Cardiovasc Pharmacol 1989; 14(Suppl 8): S93-S103.
12. Hampton J, van Veldhuisen D, Kleber F, et al. Randomised study on effect of ibopamine on survival in patients with advanced severe heart failure. Lancet 1997; 349: 971-977.
13. Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group Circulation 1993; 87 (6(Suppl): V15-16.
14. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study 390 patients Circulation 1991; 84: 40-48.
15. Middlekauff HR, Stevenson WG, Stevenson LW, Saxon LA. Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope. J Am Coll Cardiol 1993; 21: 110-116.
16. Hofmann T, Meinertz T, Kasper W, et al. Mode of death in idiopathic dilated cardiomyopathy: a multivariate analysis of prognostic determinants. Am Heart J 1988; 116 (6 Part; 1): 1455-1463.
17. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107-115.
18. Madsen BK, Hansen JF, Stokholm KH, Brons J, Husum D, Mortensen LS. Chronic congestive heart failure. Description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms. Eur Heart J 1994; 15: 303-310.
19. Girbes AJG, Zijlstra JG. Ibopamine and survival in severe congestive heart failure: PRIME II. Lancet 1997; 350: 147-148.